Visual function tests for early age-related macular degeneration
Part of Eyes & vision clinical trials.
This study looks at how well the eyes function in people with early or intermediate age-related macular degeneration (AMD). It uses imaging and vision tests to help doctors better understand the condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have 20/20 vision (with glasses or contacts) in both eyes.
- You have early or intermediate AMD in at least one eye, confirmed by the presence of drusen or pigment changes.
- You do not have advanced AMD (geographic atrophy or wet AMD) in either eye.
- You do not have other eye conditions like glaucoma or severe nearsightedness that could affect the tests.
- You do not have a neurological condition that would make vision testing difficult.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a quick, noninvasive eye test that measures how well you see in the dark, which can be an early sign of dry AMD. Researchers want to see if the test relates to everyday tasks like reading or driving at night.
This study uses specialized eye imaging to track changes in geographic atrophy, a type of vision loss from macular degeneration. Researchers will use new imaging techniques to better understand how this condition progresses and how treatments work.
This study looks at how age-related macular degeneration (AMD) affects daily activities. If you have AMD and your vision is at least 4/10, you may be able to join to help researchers understand the impact on everyday life.
This study uses artificial intelligence to track changes in the eyes of people with early or intermediate age-related macular degeneration (AMD). It aims to better understand how the disease progresses and may help doctors personalize care.
This study focuses on people age 50+ with early “wasting away” changes in the macula (central retina) called atrophic lesions. It aims to better understand how these early changes progress and how they affect vision testing, which may help improve future treatments.
This study uses eye imaging and other tests to predict if early age-related macular degeneration (AMD) will progress to a more advanced stage. It aims to help doctors identify who might need closer monitoring in the future.
Hear when a new Age-Related Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.